Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Paediatric Oncology

Guillaume Canaud, ESMO 2021: EPIK-P1 Study of Alpelisib in the Treatment Patients With PIK3CA-related Overgrowth Spectrum

Copy Link
Published Online: Oct 11th 2021

touchONCOLOGY joins Professor Guillaume Canaud (Necker–Enfants Malades Hospital, Paris, France), to discuss EPIK-P1, a retrospective chart review study of patients with PIK3CA-related overgrowth spectrum who have received alpelisib as part of a compassionate use programme.

Questions
1. Could you tell us a little about PIK3CA-related Overgrowth Spectrum (PROS), the clinical manifestations and prognosis? (00:25-01:11)
2. What is the rationale for the use of alpelisib in the treatment of patients with PROS? (01:11-01:44)
3. What were the aims, design and inclusion criteria of the EPIK-P1 study? (01:33-02:56)
4. What were the efficacy and safety findings of the study? (02:56-04:30)
5. What are the clinical implications of these findings, and what future studies are planned? (04:30-05:24)

Disclosures: TBC

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In Paediatric Oncology
Paediatric Oncology
Developed by Touch
Carmelo Rizzari: Highlights from the SIOPE Europe 2023 Annual Meeting!
Watch Time: 5 mins

President of the European Society for Paediatric Oncology (SIOPE Europe), Prof Carmelo Rizzari, discusses his highlights from the SIOPE Europe 2023 annual meeting. This year it was attended by 1200 individuals, bringing together healthcare professionals, parents, patients, caregivers, young oncologists, nurses and many other groups involved in the paediatric oncology.  There were 150 sessions and […]

Paediatric Oncology
Developed by Touch
Carmelo Rizzari: An overview of SIOP Europe
Watch Time: 25 mins

President of the European Society for Paediatric Oncology (SIOPE Europe), Prof Carmelo Rizzari, provides an interesting update on the society, the recent annual meeting, the mission and future objectives. Topics covered  SIOPE structure (01:11) Membership, Board and SIOPE Office (05:00) Initiatives and Mission (08:00) Education, AI, GDPR (09:30)  Support for survivors (12:10) SIOPE Meeting 2023 […]

Paediatric Oncology
Pamela Kearns: SIOP Europe: The Importance of Collaboration to Make Change
Watch Time: 7 mins

touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss the importance of SIOP Europe, and the power of bringing together experts, patients and parents from the continent as one voice with one objective. Questions Why is it important to have organizations like SIOP Europe? (00:21-02:09) Is there any message you would like […]

Trending In Paediatric Oncology:

Carmelo Rizzari: Highlights from the SIOPE Europe 2023 Annual Meeting!
Paediatric Oncology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72